Warning (2) : Undefined array key "profile" [in /home/marketcap/public_html/src/Controller/HomesController.php, line 242]
Warning (2) : Trying to access array offset on value of type null [in /home/marketcap/public_html/src/Controller/HomesController.php, line 242]
Warning (2) : Undefined array key "profile" [in /home/marketcap/public_html/src/Controller/HomesController.php, line 243]
Warning (2) : Trying to access array offset on value of type null [in /home/marketcap/public_html/src/Controller/HomesController.php, line 243]
Warning (512) : Unable to emit headers. Headers sent in file=/home/marketcap/public_html/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php line=36 [in /home/marketcap/public_html/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 71]
Warning (2) : Cannot modify header information - headers already sent by (output started at /home/marketcap/public_html/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php:36) [in /home/marketcap/public_html/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 168]
Warning (2) : Cannot modify header information - headers already sent by (output started at /home/marketcap/public_html/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php:36) [in /home/marketcap/public_html/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 197]
Warning (2) : Cannot modify header information - headers already sent by (output started at /home/marketcap/public_html/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php:36) [in /home/marketcap/public_html/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 236]
Viking Therapeutics, Inc. - Market capitalization
Viking Therapeutics, Inc.
VKTX

$
Marketcap
$0.00
Share price
Country
N/A
Change (1 day)
N/A
Year High
N/A
Year Low
Categories

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

marketcap

Viking Therapeutics, Inc. (VKTX) - Company Outlook